Somapacitan
- Generic Name
- Somapacitan
- Brand Names
- Sogroya
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1338578-34-9
- Unique Ingredient Identifier
- 8FOJ430U94
- Background
Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency. This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.
Somapacitan was granted FDA approval on 28 August 2020.
- Indication
Somapacitan is indicated as a replacement for growth hormone in adult patients with growth hormone deficiency.
- Associated Conditions
- Human Growth Hormone Deficiency
- Associated Therapies
- Growth Hormone Therapy
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath